Zobrazeno 1 - 10
of 19
pro vyhledávání: '"David E. Adelberg"'
Autor:
Tanios S. Bekaii-Saab, Eric Van Cutsem, Josep Tabernero, Salvatore Siena, Takayuki Yoshino, Yoshiaki Nakamura, Kanwal Pratap Singh Raghav, Andrea Cercek, Volker Heinemann, David E. Adelberg, James Edward Ward, Shan Yang, Thierry Andre, John H Strickler
Publikováno v:
Journal of Clinical Oncology. 41:TPS261-TPS261
TPS261 Background: Current standard of care (SOC) for treatment (tx) of metastatic colorectal cancer (mCRC) is multi-agent chemotherapy, w/ or w/o a VEGF- or EGFR-inhibitor. HER2 is a validated clinical target in breast and gastric cancers. HER2 ampl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa8406553b4a70c49e8c05864c5b9c3b
https://doi.org/10.1200/jco.2023.41.4_suppl.tps261
https://doi.org/10.1200/jco.2023.41.4_suppl.tps261
Publikováno v:
Therapeutics and Clinical Risk Management, Vol 2010, Iss default, Pp 579-583 (2010)
Bevin C English1, Caitlin E Baum1, David E Adelberg3, Tristan M Sissung2, Paul G Kluetz3, William L Dahut3, Douglas K Price1, William D Figg1,21Molecular Pharmacology Section, 2Clinical Pharmacology Research Core, 3Medical Oncology Branch, National C
Externí odkaz:
https://doaj.org/article/ebe109a780d3476da4d667429cb1f413
Autor:
Nancy Harold, Ravi A. Madan, David G. McLeod, Yusuke Tomita, William L. Dahut, Yunkai Yu, Min-Jung Lee, Sunmin Lee, Liang Cao, Cody J. Peer, William D. Figg, David E. Adelberg, Fatima Karzai, Howard L. Parnes, James L. Gulley, Andrea B. Apolo, Jane B. Trepel
Publikováno v:
BJU International. 116:546-555
Objective TRC105 is a chimeric immunoglobulin G1 monoclonal antibody that binds endoglin (CD105). This phase I open-label study evaluated the safety, pharmacokinetics and pharmacodynamics of TRC105 in patients with metastatic castration-resistant pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8409c7ec77073b42bb4cde72dc1a7f7
https://doi.org/10.1111/bju.12986
https://doi.org/10.1111/bju.12986
Autor:
James L. Gulley, David E. Adelberg, Ismail B. Turkbey, Cindy H. Chau, William L. Dahut, Howard L. Parnes, Peter L. Choyke, Marcia Mulquin, Joyson J. Karakunnel, Seth M. Steinberg, John Wright, William D. Figg, Shawn D. Spencer, Ravi A. Madan
Publikováno v:
BJU International. 111:1269-1280
Objective To assess the efficacy and toxicity of cediranib, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, in patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with doc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b49320cf49feae4c67bdf29171e885c
https://doi.org/10.1111/j.1464-410x.2012.11667.x
https://doi.org/10.1111/j.1464-410x.2012.11667.x
Autor:
David E Adelberg, William L Dahut
Publikováno v:
Targeted Therapies for Castration-Resistant Prostate Cancer. :22-31
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c93847507ba9d1719630a4690b0d751
https://doi.org/10.2217/ebo.11.93
https://doi.org/10.2217/ebo.11.93
Autor:
David E. Adelberg, William L. Dahut
Publikováno v:
Drug Discovery Today: Therapeutic Strategies. 7:9-15
Prostate cancer remains the most commonly diagnosed noncutaneous malignancy among men in the United States. Once prostate cancer becomes metastatic, there is no curative therapy. Angiogenesis, the process of new blood vessel formation, plays a centra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4778c5394d1f5231642b11f2a9f2c0b1
https://doi.org/10.1016/j.ddstr.2011.02.005
https://doi.org/10.1016/j.ddstr.2011.02.005
Autor:
David E. Adelberg, Michael R. Bishop
Publikováno v:
Emergency Medicine Clinics of North America. 27:311-331
As a vast majority of oncologic treatments are being administered in the outpatient setting, emergency department (ED) physicians are increasingly encountering patients who present with a wide array of toxicities that are a direct effect of chemother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e15365621a6054abe2c75b53473cca67
https://doi.org/10.1016/j.emc.2009.01.005
https://doi.org/10.1016/j.emc.2009.01.005
Autor:
Fatima H, Karzai, Andrea B, Apolo, Liang, Cao, Ravi A, Madan, David E, Adelberg, Howard, Parnes, David G, McLeod, Nancy, Harold, Cody, Peer, Yunkai, Yu, Yusuke, Tomita, Min-Jung, Lee, Sunmin, Lee, Jane B, Trepel, James L, Gulley, William D, Figg, William L, Dahut
Publikováno v:
BJU international. 116(4)
TRC105 is a chimeric immunoglobulin G1 monoclonal antibody that binds endoglin (CD105). This phase I open-label study evaluated the safety, pharmacokinetics and pharmacodynamics of TRC105 in patients with metastatic castration-resistant prostate canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c3915910472ae5a7b1e8ac02c28bbf70
https://pubmed.ncbi.nlm.nih.gov/26350576
https://pubmed.ncbi.nlm.nih.gov/26350576
Autor:
David E. Adelberg, William Dahut
Publikováno v:
Cancer Therapeutic Targets ISBN: 9781461466130
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f08aa7b2e94549e8cf50df9fbfecca60
https://doi.org/10.1007/978-1-4614-6613-0_28-2
https://doi.org/10.1007/978-1-4614-6613-0_28-2
